-->

Tag: BMS

Home / BMS

Categories

First LAG-3-Blocking antibody combination, Opdualag™ (nivolumab and relatlimab-rmbw), is approved by FDA for patients with unresectable or metastatic melanoma

April 2022: The US Food and Drug Administration (FDA) has approved Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of nivolumab and relatlimab administered as a ...
bms

Neoadjuvant nivolumab and platinum-doublet chemotherapy is approved for early-stage non-small cell lung cancer

March 2022: In the neoadjuvant setting, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with platinum-doublet chemotherapy for adult patients with resectable non-smal...
bms

Breyanzi – New CAR T-Cell therapy from BMS

July 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), a novel CD19-directed chimeric antigen receptor (CAR) T cell treatment developed by Bristol Myers Squibb (BMS), has been approved by the US Fo...
bms

Scan the code